PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
- Conditions
- Diabetes Mellitus, Type 2HealthyRenal Impairment
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT04616027
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸University of Miami Hospital, Miami, Florida, United States
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
- Conditions
- Community Acquired Pneumonia (CAP)
- Interventions
- Diagnostic Test: Urine sample collectionDiagnostic Test: Saliva collection
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1821
- Registration Number
- NCT04613375
- Locations
- 🇪🇸
Hospital Universitarios De Getafe, Getafe, Madrid, Spain
🇪🇸Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT04609319
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 827
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
Siteman Cancer Center - North County, Florissant, Missouri, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona, United States
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 234
- Registration Number
- NCT04607837
- Locations
- 🇺🇸
Tampa Bay Endoscopy Center, Tampa, Florida, United States
🇺🇸Pulmonary and Critical Care Medicine Associates (PFT only), Lemoyne, Pennsylvania, United States
🇺🇸Harrisburg Eye Associates (OCT only), Harrisburg, Pennsylvania, United States
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic ER+ HER2- Breast Cancer
- Interventions
- Drug: PF-07850327, ARV-471, vepdegestrant
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 320
- Registration Number
- NCT04606446
- Locations
- 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳SUN Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT04604496
- Locations
- 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: 14C-PF-06826647-LR 600 mg PODrug: PF-06826647 600 mg PODrug: 14C-PF-06826647 100 ug IV
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04591262
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇳🇱PRA Health Sciences Utrecht, Utrecht, Netherlands
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Sasanlimab Prefilled syringe
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT04585815
- Locations
- 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT04580797
- Locations
- 🇺🇸
Quotient Sciences, Coral Gables, Florida, United States
🇺🇸Quotient Sciences-Miami, Miami, Florida, United States